The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer. Punnen explained that the ...

CONVERGE-01 enrolled progressive PSMA-positive mCRPC after 1–6 prior Lu-177–PSMA cycles, with universal ARPI exposure and 80% prior taxane use in the ASCO cohort. Fractionated CONV01-α on days 1 and ...

Tentative FDA approval enables Lupin to prepare for commercial launch of generic enzalutamide once remaining exclusivity and patent constraints no longer block approval. Bioequivalence was established ...

Live Events | Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without ...

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. Jonathan ...

Metabolic health, especially HbA1c levels, significantly influences sexual function in aging men more than age alone. Increases in HbA1c correlate with declines in sperm motility and erectile function ...

"The landscape of prostate cancer management has evolved significantly over the past 30 years, with [active surveillance], advances in imaging and genetics, and improvements in the treatment of ...

Circulating tumor DNA (ctDNA) is a strong prognostic biomarker in the neoadjuvant setting for muscle-invasive bladder cancer. Perioperative durvalumab with neoadjuvant chemotherapy improves event-free ...

FX-909 is a small molecule PPARG inhibitor targeting advanced urothelial carcinoma, with a focus on patients with high PPARG expression. The phase 1B trial will evaluate safety, tolerability, and ...